SEC Form 4 · accession 0002064832-26-000318
Perspective Therapeutics, Inc. · CATX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Period of report
Sep 3, 2026
Accepted (ET)
Sep 8, 2026 · 4:51 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0000728387
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F2 | Sep 3, 2026 | S | 80,783 | $3.1058 | D | 11,440,513 | D | |
| Common StockF3,F2 | Sep 4, 2026 | S | 167,149 | $3.1472 | D | 11,273,364 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.05 to $3.13, inclusive. The reporting person undertakes to provide to Perspective Therapeutics, Inc. ("CATX"), any security holder of CATX or the staff of the Securities and Exchange Commission ("SEC"), upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (1) to this Form 4.
- F2Represents securities directly held by Lantheus Alpha Therapy, LLC ("Lantheus"), a wholly owned indirect subsidiary of Lantheus Holdings, Inc. ("Lantheus Holdings"). Under SEC rules and regulations, Lantheus Holdings may be deemed to have indirect beneficial ownership of the shares held by Lantheus, which has direct beneficial ownership.
- F3The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.0448 to $3.1775, inclusive. The reporting person undertakes to provide to CATX, any security holder of CATX or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (3) to this Form 4.